Phenotypes Associated with This Genotype

Genotype
MGI:3850446

• Allelic Composition: Nf2^tm2Gth/Nf2⁺; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:132943 )

• following adenoviral cre treatment, median survival time is 215 days

neoplasm

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 62% of mice develop thoracic tumors (including malignant mesothelimas, 20 of 34; and schwannomas, 1 of 34) with a longer latency than in mice homozygous for all alleles

• following adenoviral cre treatment, 21% of mice develop aspecific tumors not induced by adeno-cre treatment

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 9% of mice following adenoviral cre treatment

increased leukemia incidence ( J:132943 )

• following adenoviral cre treatment, 9% of mice develop monocytic myeloid leukemias

increased mesothelioma incidence ( J:132943 )

increased Schwannoma incidence ( J:132943 )

reproductive system

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 9% of mice following adenoviral cre treatment

muscle

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 9% of mice following adenoviral cre treatment

nervous system

increased Schwannoma incidence ( J:132943 )